3 Biotech Stocks With Enormous Catalysts Early In 2021
When it comes to stocks with the potential to make big moves in the first quarter of 2021, the author of today’s article advises that…
When it comes to stocks with the potential to make big moves in the first quarter of 2021, the author of today’s article advises that…
In a new research report, Stifel identifies its 2021 picks from the biotech sector – and today’s article highlights the five Buy-rated stocks from that…
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher…
The lesser-known ETF discussed in today’s article is already beating the market – up 185% year to date – and the author believes it will…
The small Swiss biotech firm featured in today’s article has been developing a drug that could help patients suffering from severe COVID-19 – and with…
BioXcel Therapeutics is a clinical-stage biopharmaceutical company that utilizes artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. TG Therapeutics is a biopharmaceutical company…
In regards to biotech’s bullish year, the author of today’s article notes that “The COVID-19 pandemic has put a fire under many lesser-known names, including…
A slew of biotech companies studying blood disease treatments presented data this past weekend at the annual American Society of Hematology (ASH) meeting – and,…
“In such a volatile market, it is quite difficult to find reasonably safe and high-growth biotech stocks,” acknowledges the author of today’s article. Of course,…
With the global biotechnology market expected, by one estimate, to almost double from its $448 billion level last year to $833 billion by 2027, today’s…